Deal of the year in biotech | SRPT Message Board Posts

Sarepta Therapeutics Inc.

  SRPT website

  • Important Upgrade Notice: 

    At 9 pm Central, Sunday 2/16/2020, we launched the following tools as Phase One of our Premium Plus service (full service package still under development): 

    1) Customizable Scrolling Ticker
    2) Portfolio Manager
    3) Stock-specific News & Trading Email Alert Notifications

    These products are immediately available to Precious Metal & Gemstone Patrons. 

    To watch a tutorial on the "regular" site, click here. On "premium," click here

SRPT   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  14034 of 14065  at  12/24/2019 11:45:49 AM  by


 In response to msg 14031 by  bagbest
view thread

Re: Deal of the year in biotech

It look like there's a plan to let Roche take on the RNA side of things if all goes well with GT, I suppose. Starting with DMD - the PMOs and the PPMOs.

But the PPMO can take us out of rare and into common diseases. Big populations here and abroad. Naturally that's where a Roche would fit in (both abroad and US). And other big players as well if that's how it plays out.

What ARE we doing in our PPMO RNA researches? What IS Gilmore up to? That's going to be interesting.The DMD PPMOs will get that ball rolling, but once they are out of hiding and working in the DMD kids then attention will turn to what THEY can do. Which I think is a lot, of course!

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 227
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by